EarlySight

Thank you, Venturelab, for the recognition! The entire EarlySight team is honoured to be in this selection. Congratulations to all the companies on the list - Neurosoft Bioelectronics, Bottneuro AG, CustomSurg, Adiposs, ENANTIOS, Nanoflex Robotics , Herosupport SA, FluoSphera, Artiria Medical , Avelo, TWIICE, Terapet SA — We share the same commitment to improving patients' lives 💙 and also the same incredible Swiss start-up ecosystem 🇨🇭, with its unparalleled healthtech industry 🔬 💊 🏥 🩻. Proud to be part of such an inspiring community! 🚀✨

𝐌𝐮𝐧𝐢𝐜𝐡, 𝐰𝐞'𝐫𝐞 𝐢𝐧! 🇩🇪  Our 𝐂𝐞𝐥𝐥𝐮𝐥𝐚𝐫𝐢𝐬 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 camera has found a new home at Augenklinik der Ludwig-Maximilians-Universität München! 🏥 We had the pleasure of working with the incredibly enthusiastic team of Dr. med. Maximilian-Joachim Gerhardt.  With each test image, they were already brainstorming the next big research questions and envisioning the value that 𝒉𝒊𝒈𝒉-𝒓𝒆𝒔𝒐𝒍𝒖𝒕𝒊𝒐𝒏 𝒓𝒆𝒕𝒊𝒏𝒂 𝒊𝒎𝒂𝒈𝒊𝒏𝒈 could bring to their patients. 🧠👁️  Plus, we provided a sneak peek at the beta version of our evaluation analysis software for quantifying results… stay tuned! 📊🔍  𝐃𝐚𝐧𝐤𝐞, 𝐋𝐌𝐔 𝐭𝐞𝐚𝐦! 𝐀𝐮𝐟 𝐯𝐢𝐞𝐥𝐞 𝐬𝐩𝐚𝐧𝐧𝐞𝐧𝐝𝐞 𝐄𝐧𝐭𝐝𝐞𝐜𝐤𝐮𝐧𝐠𝐞𝐧, 𝐝𝐢𝐞 𝐮𝐧𝐬 𝐞𝐫𝐰𝐚𝐫𝐭𝐞𝐧! 🍻 #MedTech #Innovation #RetinaResearch #Munich

Exciting Launch at SFITS! On Monday, October 14, we had the pleasure of attending the official launch of the Innovation Program of the SWISS Foundation for Innovation and Training in Surgery (SFITS) . “This program is designed to bring together the entrepreneurial, medical, industrial, and financial communities, creating a dynamic ecosystem where innovation can thrive.”  A special thank you to Jelena Godjevac for the invitation. 🙏✨ It was great connecting with other stakeholders, start-ups and meeting the SFITS Team. #Innovation #MedTech #Startups #Networking #SFITS #Switzerland

𝐀𝐫𝐞 𝐲𝐨𝐮 𝐜𝐨𝐦𝐢𝐧𝐠 𝐭𝐨 𝐭𝐡𝐞 𝐀𝐀𝐎 2024 𝐢𝐧 𝐂𝐡𝐢𝐜𝐚𝐠𝐨? 🌆 The team from EarlySight will be there too! Let’s dive into the world of retinal cell imaging together. Connect with  Timothé Laforest and Benedetto Sgroi to explore the latest innovations in the field. Plus, you might even learn a thing or two about Chicago’s famous deep-dish pizza from a real Italian! Don’t miss out on this chance to network, share insights, and enjoy the sights of the Windy City. Looking forward to seeing you there! 👀🍕 #aao2024 #Opthalmology #Retina #CellularResolution #Innovation

Helping is a privilege.  EarlySight is proud to contribute to the fight against avoidable blindness and visual impairment all around the world. 👁️ ✨ The second Thursday of October is the World Sight Day, time to raise awareness on the importance of eye-care and prevent vision impairment and blindness.  Approximately 90 percent of the information we obtain comes through our sense of sight, making it very difficult for us to imagine how to live without our vision. According to the WHO "𝘎𝘭𝘰𝘣𝘢𝘭𝘭𝘺, 𝘢𝘵 𝘭𝘦𝘢𝘴𝘵 2.2 𝘣𝘪𝘭𝘭𝘪𝘰𝘯 𝘱𝘦𝘰𝘱𝘭𝘦 𝘩𝘢𝘷𝘦 𝘢 𝘯𝘦𝘢𝘳 𝘰𝘳 𝘥𝘪𝘴𝘵𝘢𝘯𝘤𝘦 𝘷𝘪𝘴𝘪𝘰𝘯 𝘪𝘮𝘱𝘢𝘪𝘳𝘮𝘦𝘯𝘵. 𝘐𝘯 𝘢𝘵 𝘭𝘦𝘢𝘴𝘵 1 𝘣𝘪𝘭𝘭𝘪𝘰𝘯 𝘰𝘧 𝘵𝘩𝘦𝘴𝘦, 𝘷𝘪𝘴𝘪𝘰𝘯 𝘪𝘮𝘱𝘢𝘪𝘳𝘮𝘦𝘯𝘵 𝘤𝘰𝘶𝘭𝘥 𝘩𝘢𝘷𝘦 𝘣𝘦𝘦𝘯 𝘱𝘳𝘦𝘷𝘦𝘯𝘵𝘦𝘥 𝘰𝘳 𝘪𝘴 𝘺𝘦𝘵 𝘵𝘰 𝘣𝘦 𝘢𝘥𝘥𝘳𝘦𝘴𝘴𝘦𝘥."    At EarlySight, while doing our daily business we do not forget the people and children in need, and we do our best to develop innovative prevention tools to reduce vision loss by enabling precise detection and better monitoring of eye diseases.  #EyeHealth #RetinalImaging #EarlySight #TechForGood #CellularResolution       

📢 EarlySight Welcomes Jerome Martinez as Independent Board Member 🚀 EarlySight is thrilled to announce the appointment of Jérôme Martinez as an independent board member. With his deep expertise and proven leadership in the pharmaceutical, biotechnology, and medical device sectors, Jérôme will play a pivotal role in helping EarlySight navigate its next phase of growth and development. He will lend his insight to advance Early Sight’s groundbreaking cellular level imaging technology, working to make it a routine diagnostic tool in modern healthcare. Jérôme Martinez brings over 30 years of international experience, currently serving on the boards of MDoloris, Theranexus, and ErVimmune. His extensive track record includes leadership roles at major healthcare companies. As for Ophthalmology, he led the French operations of SANTEN, a Japanese pharmaceutical company specializing in ophthalmology and rheumatology, from 2012 to 2017. Notably, Jérôme was Chairman of the Executive Board at Novagali Pharma from 2004 to 2011, where he successfully managed its IPO and subsequent acquisition by SANTEN. Under his leadership, Novagali Pharma secured the first European marketing authorization for an ophthalmic cyclosporine treatment. Jérôme holds a Doctor of Pharmacy degree, a Master’s in Health Administration Law from the University of Paris XI, and an MBA from both HEC Paris and Keio Business School in Tokyo. He has further sharpened his business acumen through executive programs at Northwestern University's JL Kellogg Graduate School of Management and at INSEAD where he got a Certificate in Corporate Governance attending the International Director Program. We are confident that Jérôme's wealth of experience and strategic vision will be instrumental in propelling EarlySight towards its mission of revolutionizing retinal imaging. #ophthalmology #governance #medicaldevice #diagnosis

Since the inception of EarlySight, we have consistently attended the Euretina Congress, and the traction around our booth this year is a clear sign of the growing interest in adaptive optics within the community. Single-cell imaging is yet to become the reference modality, but it’s too important to miss. 👁️✨ The event brought together key players in retina care, providing a valuable opportunity to engage with the entire spectrum of stakeholders—ophthalmologists, optometrists, pharma, fellow medical device companies, and distributors. The outcome of this event goes beyond opening new business opportunities; it has also sparked a renewed wave of enthusiasm as we continue our mission to transform Adaptive Optics imaging from a sophisticated laboratory tool into a clinically relevant and user-friendly device: 𝐂𝐞𝐥𝐥𝐮𝐥𝐚𝐫𝐢𝐬 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲. 🚀🔬 A special thanks to our dedicated users who presented at #Euretina24: Aude Ambresin, Andrea Cusumano, Francine Behar-Cohen, and Mihaela Chitoroaga 🙌 And a big thank you to our distributors: ALPHA EYES , Biomed Healthcare & MedTech Consulting, EMETROP', Instinctive Limited, Hongda Medical Equipment, OftalMedica, OftalTech Solutions Lastly, our gratitude to the European Society of Retina Specialists (EURETINA) for organizing such an outstanding event. 👏👏

📢 EarlySight is excited to announce to attend the highly anticipated  #EURETINA24 congress (booth E.2.4) in Barcelona, Spain. ✨Don't miss this chance to meet Timothé Laforest and Benedetto Sgroi to discover our ophthalmological imaging tool, Cellularis Discovery, which is able to see the eye fundus as never seen before, down to the cellular level. 👁️ Check out our esteemed lineup of abstracts presented by our clinical research teams partners to gain valuable knowledge about the unique benefits and potential of using 𝐀𝐝𝐚𝐩𝐭𝐢𝐯𝐞 𝐎𝐩𝐭𝐢𝐜𝐬-𝐓𝐫𝐚𝐧𝐬𝐬𝐜𝐥𝐞𝐫𝐚𝐥 𝐅𝐥𝐨𝐨𝐝 𝐈𝐥𝐥𝐮𝐦𝐢𝐧𝐚𝐭𝐢𝐨𝐧 to answer the need for precision medicine in ophthalmology. Abstracts: 𝘊𝘈24-2656-10056, 𝘓𝘉24-135-1492, 𝘊𝘈24-2256-9846 .   Special thanks to Aude Ambresin , Francine Behar-Cohen , Andrea Cusumano  for sharing their research! Connecting with EarlySight at the 24th Euretina Conference promises to be an invaluable opportunity to stay updated on our latest developments in ophthalmological imaging. #ophthalmology #medicalimaging #retina #FONGIT #EURETINA24

🎉 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐍𝐞𝐰𝐬! 🎉   We’re proud to share that EarlySight has been ranked among the 𝐓𝐨𝐩 100 𝐒𝐰𝐢𝐬𝐬 𝐒𝐭𝐚𝐫𝐭-𝐮𝐩𝐬 𝐨𝐟 2024  #Top100SSU , placing 6𝐭𝐡 𝐢𝐧 𝐭𝐡𝐞 𝐌𝐞𝐝𝐓𝐞𝐜𝐡 𝐜𝐚𝐭𝐞𝐠𝐨𝐫𝐲 and 48𝐭𝐡 𝐨𝐯𝐞𝐫𝐚𝐥𝐥! 🎉     🔍 𝐖𝐡𝐲 𝐄𝐚𝐫𝐥𝐲𝐒𝐢𝐠𝐡𝐭 𝐜𝐨𝐧𝐯𝐢𝐧𝐜𝐞𝐝 𝐭𝐡𝐞 𝐣𝐮𝐫𝐲 𝐭𝐡𝐢𝐬 𝐲𝐞𝐚𝐫?  Our mission is clear: 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦 𝐭𝐡𝐞 𝐞𝐚𝐫𝐥𝐲 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝐞𝐲𝐞 𝐝𝐢𝐬𝐞𝐚𝐬𝐞𝐬 through unparalleled imaging technology. In April 2023, we launched production of our flagship product, 𝐂𝐞𝐥𝐥𝐮𝐥𝐚𝐫𝐢𝐬 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲, which sold out in its first run! 🚀 This advanced retinal camera offers 𝐭𝐞𝐧𝐟𝐨𝐥𝐝 𝐢𝐦𝐚𝐠𝐞 𝐫𝐞𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧 compared to current standards, and we are the only company with patented 𝐀𝐝𝐚𝐩𝐭𝐢𝐯𝐞 𝐎𝐩𝐭𝐢𝐜𝐬 𝐓𝐫𝐚𝐧𝐬𝐬𝐜𝐥𝐞𝐫𝐚𝐥 𝐅𝐥𝐨𝐨𝐝 𝐈𝐥𝐥𝐮𝐦𝐢𝐧𝐚𝐭𝐢𝐨𝐧 (𝐀𝐎-𝐓𝐅𝐈) technology, allowing unprecedented observation of RPE cells.   💡 𝐊𝐞𝐲 𝐀𝐜𝐡𝐢𝐞𝐯𝐞𝐦𝐞𝐧𝐭𝐬:   👉 A dedicated 𝐭𝐞𝐚𝐦 that delivers, overcoming the challenges of a start-up.  👉 Over 600 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 have been examined using our technology, yielding invaluable insights into retinal pathologies.   👉 Exciting new collaborations with pharma companies who see cellular-resolution imaging as essential for developing 𝐭𝐡𝐞 𝐧𝐞𝐱𝐭 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭𝐬.   Thank you to our amazing team, partners and customers for believing in our vision and helping us reach new heights. We’re excited for what’s next!     The 𝐓𝐨𝐩 100 𝐒𝐰𝐢𝐬𝐬 𝐒𝐭𝐚𝐫𝐭-𝐮𝐩 𝐀𝐰𝐚𝐫𝐝 is a benchmark event, highlighting Switzerland’s most promising and innovative ventures. Over the past decade, 553 deep-tech start-ups have featured in the ranking, creating nearly 19,000 jobs and raising over CHF 13.6 billion. We’re honoured to be part of this incredible community, recognized by a jury of investors, successful entrepreneurs, and key ecosystem stakeholders.      #Innovation  #StartupJourney #Top100SwissStartups #MedTech #Innovation #EyeHealth #RetinalImaging #EarlySight #CellularResolution   

✨ We are thrilled to announce that Instinctive Limited (UK) signed a distribution agreement with EarlySight.   Instinctive (UK) is the exclusive distributor and licensee for the sale and distribution of the Cellularis Discovery in the United Kingdom and Ireland.   EarlySight is proud to work with Instinctive. Established in 1991, Instinctive is specialized on refractive lasers and associated diagnostic tools. Its experienced, clinically focused sales specialists are supported by a skilled team of manufacturer-trained service engineers.   Thank to this collaboration Cellularis Discovery can be used as research tool in further clinical trials and research in the United Kingdom and Ireland.  #ophthalmology #imaging #retina